Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Cariprazine, a potent dopamine D(3) and D(2) receptor partial agonist antipsychotic with preferential binding to D(3) receptors, is Food and Drug Administration approved for treating schizophrenia and manic or mixed episodes of bipolar I disorder. A post-hoc safety/tolerability analysis of data from...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int Clin Psychopharmacol
Hlavní autoři: Earley, Willie, Durgam, Suresh, Lu, Kaifeng, Laszlovszky, István, Debelle, Marc, Kane, John M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams And Wilkins 2017
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5625952/
https://ncbi.nlm.nih.gov/pubmed/28692485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0000000000000187
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky